Southeastern regional Medical Center

Newnan, Georgia 30265-8001

2 studies enrolling now · 22 studies all time

What they study most

Advanced Breast Cancer, B-cell Lymphoma, B-cell Malignancy, Breast Cancer, Breast Neoplasms, CLL, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Early Breast Cancer, Endometrial Carcinoma, Follicular Lymphoma, Gastric, or Gastroesophageal Junction Adenocarcinoma

Studies at this site

• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — Recruiting now
• A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) — Recruiting now
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) — Running, not enrolling
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — Running, not enrolling
• A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer — Stopped early
• Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects — Running, not enrolling
• Study of Magrolimab in Patients With Solid Tumors — Stopped early
• Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma — Completed
• Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer — Completed
• MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors — Completed
• A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer — Completed
• A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer — Completed
• Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer — Completed
• Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma — Completed
• BKM120 for Patients With PI3K-activated Tumors — Completed
• NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer — Status unconfirmed
• M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer — Stopped early
• Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer — Completed
• Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall — Completed
• MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients — Stopped early
• Improved Method of Detecting Cancer Metastases — Status unconfirmed